Home > News > BioSante Reports Product Highlights and Financial Results
May 12th, 2006
BioSante Reports Product Highlights and Financial Results
Abstract:
"We were pleased to start the year by submitting our new drug application for Bio-E-Gel(R), which we believe, if and when approved, may offer the lowest effective dose of estrogen on the market for the treatment of hot flashes," said Stephen M. Simes, BioSante's president and chief executive officer. "Also in the first quarter, positive data from pre-clinical trials with BioVant(TM), our calcium phosphate nanoparticle technology, demonstrated its effectiveness as an adjuvant for flu vaccines, including bird flu. Looking to the remainder of 2006, we aim to continue our success by initiating Phase III clinical studies of LibiGel(R) in female sexual dysfunction."
Source:
businesswire
Bookmark:
| Related News Press |
Products
Spectradyne Partners with Particle Technology Labs for Measurement Services December 6th, 2018
Mode-Changing MEMS Accelerometer from STMicroelectronics Combines High Measurement Resolution and Ultra-Low Power for Industrial Applications November 7th, 2018
Fat-Repellent Nanolayers Can Make Oven Cleaning Easier October 17th, 2018
Aculon, Inc. Enters into Strategic Partnership Agreement with Henkel Corporation to Supply Key Mobile Device Manufacturers with NanoProof® PCB Waterproof Technology October 17th, 2018
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Rice membrane extracts lithium from brines with greater speed, less waste October 3rd, 2025
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||